REFERENCES
  1. Moschcowitz, E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc. N. Y. Pathol. Soc. 24, 21–24 (1924).
  2. Soejima, K. et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J. Biochem. 130, 475–480 (2001).
  3. Schulman, I., Pierce, M., Lukens, A. & Currimbhoy, Z. Studies on thrombopoiesis. I: a factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 16, 943–957 (1960). 17.
  4. Upshaw, J. D. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N. Engl. J. Med. 298, 1350–1352 (1978).
  5. Scully, M. et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br. J. Haematol. 158, 323–335 (2012). 106.
  6. Matsumoto, M. et al. Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS ONE 7, e33029 (2012).
  7. Rock, G. A. et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N. Engl. J. Med. 325, 393–397 (1991).
  8. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339 (22):1585-1594. [PMC free article] [PubMed] [Google Scholar]
  9. Tsai, HM.; Chapter 49: Thrombotic Thrombocytopenic purpura, Hemolytic-Uremic Syndrome, and Related Disorders. In Wintrobe,s Clinical Hematology, 14th ed.; Greer, J.P., Glader, B.E., List, A.F., Means, R.M, Rodgers, G.M., Eds.; Wolters Kluwer: Philadelphia, PA, USA, 2019; pp. 3434-3510
  10. Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010;91(1):1-19
  11. Arboix A, Besses C. Cerebrovascular disease as the initial clinical presentation of haematological disorders. Eur Neurol. 1997;37(4):207-211.
  12. Burrus TM, Wijdicks EF, Rabinstein AA. Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura. Neurology. 2009;73(1):66-7
  13. Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int. 2006;70(1):16
  14. Tanner L. Muller MM. [Blood Transfusion: a guide to Clinical Decision making] Anasthesiol Intensivmed Notfallmed Schmerzther. 2019 Mar;54(3): 194-205. [PubMed]
  15. Coppo P, Cuker A, George JN. Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2019 Jan; 3(1):26-37 [PMC free article] [PubMed}
  16. Wiernek SL, Jiang B, Gustafson GM, Dai X. cardiac implications of thrombotic thrombocytopenic purpura. World J Cardiol. 2018 Dec 26;10(12):254-266. [PMC free article] [PubMed]
  17. Bendapudi PK, Huwitz S, Fry A, Marques MB, Waldo SW, Li A, et al. Derivation and external validation of the PLASMIC score for rapid assessment with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017; 4:157-64.
  18. Bendapuli PK, Makar RS. An algorithmic approach to the diagnosis and management of the thrombotic microangiopathies. Am J Clin Pathol. 2016; 145:152-4
  19. Polito MG, Kirsztajn GM. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome. J Bras Nefrol. 2010;32(3):303-315. 24.
  20. Kiss JE. Thrombotic thrombocytopenic purpura: recognition and management. Int J Hematol. 2010;91(1):36-45
  21. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):393-397
  22. Kiss JE. Thrombotic thrombocytopenic purpura: recognition and management. Int J Hematol. 2010;91(1):36-45.
  23. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher. 2006;21(1):49-56.
  24. Cataland SR, Jin M, Ferketich AK, Kennedy MS, Kraut EH, George JN, Wu HM. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2007;136(1):146-149.